Samsung Biologics promoted a total of six people through its 2026 executive appointments, including two executive vice presidents and four executive directors.
The company said the appointments focused on securing future growth engines and strengthening global competitiveness amid an uncertain global environment.
First, Executive Vice President Kim Hee-jeong was promoted for leading a stable drug substance (DS) production system despite new plant expansions and increased production scale.
Executive Vice President Jung Hyung-nam, who has led the antibody-drug conjugate (ADC) business and contributed to strengthening the contract development (CDO) business's competitiveness by launching new services and developing proprietary antibody technology, was also promoted.
In addition, Executive Director An So-yeon, who contributed to achieving full operation early and expanding sales by streamlining production process and schedule management after the completion of Plant 4, and Executive Director Yu Dong-seon, who enhanced technology transfer competitiveness by improving manufacturing science and technology (MSAT) procedures, were promoted to new executive posts.
Cha Young-pil and Hwang Jun-ho were also appointed as new executives to effectively support system buildout and overall business operations for advancing the manufacturing execution system (MES).
Samsung Biologics emphasized that Executive Vice President Kim Hee-jeong and Executive Director An So-yeon, in their 40s and 30s respectively, are the youngest female executives since the company's founding.
The following is the list of Samsung Biologics executive promotions.
◇ Executive vice president
▲ Kim Hee-jeong ▲ Jung Hyung-nam
◇ Executive director
▲ An So-yeon ▲ Yu Dong-seon ▲ Cha Young-pil ▲ Hwang Jun-ho